Sarcomatoid Renal Cell Carcinoma in a Renal Transplant Recipient

Llamas, Francisco; Gallego, Eduardo; Salinas, Alejandro Montero; Vírseda, Juan Antonio Vicente; Pérez, Juan; Ortega, Antonio Osuna; Nam, Syonghun; Gómez, Carmen

doi:10.1016/j.transproceed.2009.08.066

Cited by 13 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median age of recipients was 47 years (range 9-66), and 27% were females. The cause for renal transplant were: chronic glomerulonephritis (22%, n=6), 6-10 polycystic kidney disease (11%, n=3), 8,11,12 hypertension (11%, n=3), 13,14 IgA nephropathy (8%, n=2), 10 renal pelvis carcinoma with left nephrectomy (4%, n=1), 15 nephronopthisis (4%, n=1), 16 congenital nephrotic syndrome (4%, n=1), 10 amyloid disease (4%, n=1), 17 diabetes mellitus (4%, n=1), 6 interstitial nephritis (4%, n=1), 18 Henoch-Schonlen purpura (4%, n=1), 19 Alport syndrome (4%, n=1), 18 neurogenic bladder (4%, n=1), obstructive uropathy (4%, n=1) and ESRD of unknown origin (8%, n=2). 20,21 …”

Section: Review Of Reported Casesmentioning

confidence: 99%

“…The most common type of RCC was clear cell carcinoma (27%, n=9) 7,10,12-14,20,21,31 while the other types were: sarcomatoid (15%, n=5), 2,8 angiosarcoma (6%, n=2), 18 renal papillary tumor (6%, n=2), 28,31 anaplastic (6%, n=2), 25,29 chromophobe (3%, n=1), 16 cystic adenocarcinoma (3%, n=1), 31 anaplastic adenocarcinoma (3%, n=1), 29 giant and spindle cell carcinoma (3%, n=1), 15 and undifferentiated (6%, n=2). 17,22 The type of renal cell carcinoma was not mentioned in the rest (22%, n=7), 2,6,19,31 Other tumors (31%, n=15) comprised 31% of the cases which included: undifferentiated cancer (20%, n=3), 6 invasive urothelial carcinoma (7%, n=1), 24 papillary transitional cell carcinoma of bladder (7%, n=1).…”

Section: Review Of Reported Casesmentioning

confidence: 99%

“…Actuarial 1-year and 5-year survival rates were 73.4% and 55.1% respectively. Out of eleven recipients, who died after transplant, 9 were due to malignancy-related causes, 6,8,11,15,17,18,24,26,29 while 2 were due to other causes. 2 The recipient in Llamas et al .…”

Section: Review Of Reported Casesmentioning

confidence: 99%

See 2 more Smart Citations

Renal Cancer in Recipients of Kidney Transplant

et al. 2016

View full text Add to dashboard Cite

The aim of our study is to determine characteristics and outcomes of kidney cancer in renal transplant recipients. MEDLINE® database was searched in June 2015 to identify cases of kidney cancer in renal transplant recipients. We include also a new case. Descriptive statistics were used for analysis. Forty-eight (48) recipients reported in 25 papers met the eligibility criteria. The median age was 47 years (range 9-66); 27% were females. Chronic glomerulonephritis, cystic kidney disease and hypertension were common indications for renal transplant. Among donors 24% were females and the median age was 52.5 years (17-73); 62% of kidney cancers were donor-derived. The median interval between transplant and cancer diagnosis was shorter for cancer of recipient versus donor origin (150 vs. 210 days). Clear cell carcinoma was diagnosed in 17%. 25% had metastasis at diagnosis. Kidney explantation or excision was done in 90% and 84% of cases with and without metastasis respectively. The median survival was 72 months. Actuarial 1-year and 5-year survival rates were 73.4% and 55.1% respectively. Among the recipients from 7 donors who subsequently developed malignancy, 57% were dead within a year. Kidney transplant recipients have a small risk of kidney cancer, which affects younger patients and occurs within a year of transplant, likely due to immunosuppression. Whether the use of older donors may increase the likelihood needs further investigation. The presence of metastasis, explantation or excision of affected kidney and development of cancer in donors predict outcomes. The results may guide patient education and informed decision-making.

show abstract

Section: Review Of Reported Casesmentioning

confidence: 99%

Section: Review Of Reported Casesmentioning

confidence: 99%

See 1 more Smart Citation

Renal Cancer in Recipients of Kidney Transplant

et al. 2016

View full text Add to dashboard Cite

show abstract

“…It is more likely to occur in a native kidney of a transplant recipient than in the transplanted kidney. [1][2][3][4] The first case of a de novo tumor arising in a transplanted kidney was reported in 1988. 5 The incidence was reported to be 0.19% to 0.5%.…”

Section: Figurementioning

confidence: 99%

“…5 The incidence was reported to be 0.19% to 0.5%. [2][3][4]6,7 The mean time lapse between kidney transplantation and de novo RCC in the allograft varied between 3 and 17 years. [7][8][9] There is a better prognosis if RCC is detected early by screening.…”

Section: Figurementioning

confidence: 99%

Renal Cell Carcinoma Arising From Renal Allograft Detected by 18F-FDG PET-CT

Guo

Wang²

2016

Clinical Nuclear Medicine

View full text Add to dashboard Cite

Renal cell carcinoma arising from renal allograft is a rare condition. A 56-year-old man with a history of 3 renal transplantation due to renal failure presented poor appetite and weight loss for 3 months. Possibility of tumor of unknown origin was suspected. For this reason, an FDG PET/CT was performed, and the images showed a hypermetabolic focus in the lower pole of the left renal transplant, suggestive of a malignant lesion. Subsequent pathological examination following allograft nephrectomy confirmed grade 4 renal cell carcinoma.

show abstract

Organ Donor Risk Stratification in Italy

Peris

Bronzoni

Meli

et al. 2020

Textbook of Patient Safety and Clinical Risk Management

View full text Add to dashboard Cite

The permanent gap between organ demand and supply has prompted use of organs from extended criteria donors (ECD). These carry a higher risk of disease transmission, with regard to infections and malignancies. We present herein the donor risk stratification algorithm implemented in Italy since 2004 for identification management of donor-to-recipient risk of disease transmission. The principles underlying this algorithm are: (1) the risk of disease transmission must be assessed against the potential benefit for the transplant recipient (i.e., no donor can be excluded from evaluation and their organs might benefit potential candidates); (2) patients awaiting organ transplantation must be informed that the risk of disease transmission is small but finite (standard risk); and (3) risk evaluation is an ongoing process based on information collected longitudinally after transplantation. Regional and national transplant authorities are committed to regular updating of guidelines based on clinical data derived from clinicians and on evaluation of posttransplant graft and patient survival rates.

show abstract

Sarcomatoid Renal Cell Carcinoma in a Renal Transplant Recipient

Cited by 13 publications

References 12 publications

Renal Cancer in Recipients of Kidney Transplant

Renal Cancer in Recipients of Kidney Transplant

Renal Cell Carcinoma Arising From Renal Allograft Detected by 18F-FDG PET-CT

Organ Donor Risk Stratification in Italy

Contact Info

Product

Resources

About